Somatic mutation of fibroblast growth factor receptor‐3 ( FGFR3 ) defines a distinct morphological subtype of high‐grade urothelial carcinoma
Open accessAbstract
FGFR3 mutations are common in low‐grade urothelial carcinoma and represent a potential therapeutic target in this disease. Their incidence and functional role in high‐grade urothelial carcinoma (HGUC), which displays an increased propensity for recurrence and muscularis propria invasion, is less well defined. We developed a mass spectrometry‐based genotyping assay to define the incidence of FGFR3 mutations in a large clinically annotated set of urothelial carcinomas. FGFR3 mutations were found in 17% of HGUC versus 84% of low‐grade lesions. Retrospective pathological review of the class of FGFR3 mutant HGUC revealed unique histological features, characterized by a bulky, exophytic component with branching papillary architecture as well as irregular nuclei with a koilocytoid appearance. The predictive value of this histological appearance was confirmed using a prospective set of 49 additional HGUCs. Prospective histological review was able to correctly predict for the presence of an FGFR3 mutation in 13/24 HGUC specimens that exhibited the distinct morphology (54%). All 25 specimens lacking the defined histological features were FGFR3 wild‐type for a negative predictive value of 100%. Macrodissection of individual tumours confirmed the presence of the FGFR3 mutant allele in non‐invasive and invasive, low and high‐grade regions of individual tumours and in the lymph node metastases of patients whose tumours possessed the characteristic morphological signature, suggesting that FGFR3 mutations are not restricted to the more clinically indolent regions of HGUCs. These data suggest that histological screening of HGUCs followed by confirmatory genotyping can be used to enrich for the population of HGUCs most likely to harbour activating mutations in the FGFR‐3 receptor tyrosine kinase. Histological review could thus aid in the development of targeted inhibitors of FGFR‐3 by facilitating the identification of the subset of patients most likely to harbour activating mutations in the FGFR3 gene. Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Anecdotal experience from pathologists suggested there may be a morphological signal for FGFR alterations.
“Anecdotal experience from pathologists suggested there may be a morphological signal for FGFR alterations66.”
From A foundation model for clinical-grade computational pathology and rare cancers detection (2024) · cites this paper as [66]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · see citing works
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709 · see citing works
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · see citing works
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389 · see citing works
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · see citing works
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I. J., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,542 · see citing works
Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients
Stein, J. P., Lieskovsky, G., Cote, R., Groshen, S. G., Feng, A., Boyd, S. D., Skinner, E. C., Bochner, B. H., Thangathurai, D., Mikhail, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.666 · Cited by 3,527 · see citing works
Self-citationLapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J. K., Lindquist, D. L., Chan, S. Y. T., Romieu, C. G., Pieńkowski, T., Jagiełło-Gruszfeld, A., Crown, J. P., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,426 · see citing works
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,592 · see citing works
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
Tsao, M., Sakurada, A., Cutz, J.-C., Zhu, C., Kamel‐Reid, S., Squire, J. A., Lorimer, I. A. J., Zhang, T., Liu, G., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,815 · see citing works
Epstein, J. I., Amin, M. B., Reuter, V. R., & Mostofi, F. K. (1998) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199812000-00001 · Cited by 1,576 · see citing works
Self-citationKRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
Pao, W. J., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., Zakowski, M. F., Heelan, R. T., Kris, M. G., & VARMUS, H. E. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020017 · Cited by 1,517 · see citing works
The health economics of bladder cancer
Botteman, M. F., Pashos, C. L., Redaelli, A. C. L., Laskin, B. L., & Hauser, R. S. (2003) · PharmacoEconomics · doi:10.1007/bf03262330 · Cited by 866 · see citing works
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas
Cappellen, D., de Oliveira, C. C. B., Ricol, D., de Medina, S. D., Bourdin, J., Sastre-Garau, X., Chopin, D., Thiery, J., & Radvanyi, F. (1999) · Nature Genetics · doi:10.1038/12615 · Cited by 743 · see citing works
Translation of the Philadelphia chromosome into therapy for CML
Druker, B. J. (2008) · Blood · doi:10.1182/blood-2008-07-077958 · Cited by 665 · see citing works
The Treated Natural History of High Risk Superficial Bladder Cancer: 15-year Outcome
Cookson, M. S., Herr, H. W., Zhang, Z., Soloway, S. M., Sogani, P. C., & Fair, W. R. (1997) · The Journal of Urology · doi:10.1097/00005392-199707000-00017 · Cited by 547 · see citing works
Frequent FGFR3 Mutations in Papillary Non-Invasive Bladder (pTa) Tumors
Billerey, C., Chopin, D. K., Aubriot‐Lorton, M., Ricol, D., de Medina, S. G. D., van Rhijn, B., Bralet, M., Frère‐Belda, M. L., Lahaye, J.-B., Abbou, C. C., et al. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64665-2 · Cited by 498 · see citing works
Economic aspects of bladder cancer: what are the benefits and costs?
Sievert, K. D., Amend, B., Nagele, U., Schilling, D., Bedke, J., Horstmann, M., Hennenlotter, J., Kruck, S., & Stenzl, A. (2009) · World Journal of Urology · doi:10.1007/s00345-009-0395-z · Cited by 485 · see citing works
Tomlinson, D. C., Baldo, O., Harnden, P., & Knowles, M. A. (2007) · The Journal of Pathology · doi:10.1002/path.2207 · Cited by 362 · see citing works
Hernandez, S. F., López‐Knowles, E., Lloreta, J., Kogevinas, M., Amorós, À., Tardón, A., Carrato, A., Serra, C., Malats, N., & Real, F. X. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1771 · Cited by 334 · see citing works
van Rhijn, B. V., Vis, A. N., van der Kwast, T., Kirkels, W., Radvanyi, F., Ooms, E. C., Chopin, D., Boevé, E., Jöbsis, A. C., & Zwarthoff, E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.073 · Cited by 331 · see citing works
FGFR activation in skeletal disorders: Too much of a good thing
Webster, M. K. (1997) · Trends in Genetics · doi:10.1016/s0168-9525(97)01131-1 · Cited by 320 · see citing works
Roles of Fibroblast Growth Factor Receptors in Carcinogenesis
Haugsten, E. M., Więdłocha, A., Olsnes, S., & Wesche, J. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0168 · Cited by 315 · see citing works
Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer
Janakiraman, M., Vakiani, E., Zeng, Z., Pratilas, C. A., Taylor, B. S., Chitale, D., Halilovic, E., Wilson, M., Huberman, K., Ricarte Filho, J. C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0192 · Cited by 290 · see citing works
Self-citationGenetic Predictors of MEK Dependence in Non–Small Cell Lung Cancer
Pratilas, C. A., Hanrahan, A. J., Halilovic, E., Persaud, Y., Soh, J., Chitale, D. A., Shigematsu, H., Yamamoto, H., Sawai, A., Janakiraman, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2223 · Cited by 252 · see citing works
Self-citationRoberts, P. J., Stinchcombe, T. E., Der, C. J., & Socinski, M. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4365 · Cited by 240 · see citing works
Herr, H. W. (2000) · The Journal of Urology · doi:10.1016/s0022-5347(05)67972-4 · Cited by 221 · see citing works
Tumour progression and survival in patients with T1G3 bladder tumours: 15‐year outcome
Herr, H. W. (1997) · British Journal of Urology · doi:10.1046/j.1464-410x.1997.00431.x · Cited by 172 · see citing works
van Rhijn, B. V., van Tilborg, A. V., Lurkin, I., Bonaventure, J., de Vries, A., Thiery, J., van der Kwast, T., Zwarthoff, E., & Radvanyi, F. (2002) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5200883 · Cited by 155 · see citing works
Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer
Tomlinson, D., Hurst, C., & Knowles, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210399 · Cited by 142 · see citing works
Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target
Knowles, M. A. (2007) · World Journal of Urology · doi:10.1007/s00345-007-0213-4 · Cited by 129 · see citing works
Smits, G. A. H. J., Schaafsma, E., Kiemeney, L. A. L. M., Caris, C. T. M., Debruyne, F. M. J., & Witjes, J. A. (1998) · Urology · doi:10.1016/s0090-4295(98)00374-4 · Cited by 124 · see citing works
Masuya, D., Huang, C., Liu, D., Kameyama, K., Hayashi, E., Yamauchi, A., Kobayashi, S., Haba, R., & Yokomise, H. (2001) · Cancer · doi:10.1002/1097-0142(20011115)92:10 · Cited by 122 · see citing works
di Martino, E., L’Hôte, C., Kennedy, W., Tomlinson, D. C., & Knowles, M. A. (2009) · Oncogene · doi:10.1038/onc.2009.280 · Cited by 108 · see citing works
Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib
Demetri, G. D. (2002) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(02)00052-7 · Cited by 62 · see citing works
Martínez‐Frías, M. L., de Frutos, C. A., Bermejo, E., ECEMC Working Group, & Nieto, M. A. (2009) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.33188 · Cited by 38 · see citing works
Grossman, H. B., O’Donnell, M. A., Cookson, M. S., Greenberg, R. E., & Keane, T. E. (2008) · Europe PMC (PubMed Central) · Cited by 32 · see citing works
Barton, S. R., Starling, N., & Swanton, C. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910793357925 · Cited by 30 · see citing works
State of the art in comparative cancer clinical trials
Begg, C. B., Pocock, S., Freedman, L. S., & Zelen, M. (1987) · Cancer · doi:10.1002/1097-0142(19871201)60:11 · Cited by 20 · see citing works
Milowsky, M. I., Stadler, W. M., & Bajorin, D. F. (2008) · British Journal of Urology · doi:10.1111/j.1464-410x.2008.07980.x · Cited by 17 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
The Fibroblast Growth Factor signaling pathway
Ornitz, D. M., & Itoh, N. (2015) · WIREs Developmental Biology · doi:10.1002/wdev.176 · Cited by 2,050 · see citing works
Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer
Lee, S. H., Hu, W., Matulay, J. T., Silva, M. V., Owczarek, T. B., Kim, K., Chua, C. W., Barlow, L. J., Kandoth, C., Williams, A. B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.017 · Cited by 873 · see citing works
Self-citationA foundation model for clinical-grade computational pathology and rare cancers detection
Vorontsov, E., Bozkurt, A., Casson, A., Shaikovski, G., Zelechowski, M., Severson, K., Zimmermann, E., Hall, J., Tenenholtz, N., Fusi, N., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03141-0 · Cited by 572 · see citing works
Targeting FGFR Signaling in Cancer
Touat, M., Ileana, E. E., Postel-Vinay, S. C., André, F., & Soria, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2329 · Cited by 531 · see citing works
Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
Dienstmann, R., Rodon, J. A., Prat, A., Pérez-García, J. M., Adamo, B., Felip, E., Cortés, J., Iafrate, A. J., Nuciforo, P. G., & Tabernero, J. M. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt419 · Cited by 370 · see citing works
Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up
Joaquim Bellmunt, B., Anna Orsola, A., Leow, J. J. J., Wiegel, T., Santis, M. D., & Horwich, A. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu223 · Cited by 335 · see citing works
Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer
Iyer, G., Al‐Ahmadie, H. A., Schultz, N. D., Hanrahan, A. J., Ostrovnaya, I., Balar, A. V., Kim, P. H., Lin, O., Weinhold, N., Sander, C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.5740 · Cited by 305 · see citing works
Self-citationGenomic Characterization of Upper Tract Urothelial Carcinoma
Sfakianos, J. P., Cha, E. K., Iyer, G., Scott, S. N., Zabor, E. C., Shah, R. H., Ren, Q., Bagrodia, A., Kim, P. H., Hakimi, A. A., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.07.039 · Cited by 288 · see citing works
Self-citationBladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up
Joaquim Bellmunt, B., Anna Orsola, A., Maldonado, X., & Kataja, V. V. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq175 · Cited by 162 · see citing works
Ross, J. S., Wang, K., Al-Rohil, R. N., Nazeer, T., Sheehan, C. E., Otto, G. A., He, J., Palmer, G. A., Yelensky, R., Lipson, D., et al. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.135 · Cited by 147 · see citing works
Chell, V., Balmanno, K., Little, A. S., Wilson, M. I., Andrews, S., Blockley, L., Hampson, M., Gavine, P. R., & Cook, S. J. (2012) · Oncogene · doi:10.1038/onc.2012.319 · Cited by 143 · see citing works
Nakanishi, Y., Akiyama, N., Tsukaguchi, T., Fujii, T., Sakata, K., Sase, H., Isobe, T., Morikami, K., Shindoh, H., Mio, T., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0248 · Cited by 122 · see citing works
FGFR3 Stimulates Stearoyl CoA Desaturase 1 Activity to Promote Bladder Tumor Growth
Du, X., Wang, Q.-R., Chan, E., Merchant, M. A., Liu, J., French, D. M., Ashkenazi, A., & Qing, J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1329 · Cited by 108 · see citing works
FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder
Guancial, E. A., Werner, L. L., Joaquim Bellmunt, B., Bamias, A., Choueiri, T. K., Ross, R. W., Schutz, F. A. B., Park, R. S., O'Brien, R. J., Hirsch, M. S., et al. (2014) · Cancer Medicine · doi:10.1002/cam4.262 · Cited by 92 · see citing works
Apolo, A. B., Ostrovnaya, I., Halabi, S., Iasonos, A. E., Philips, G. K., Rosenberg, J. E., Riches, J. C., Small, E. J., Milowsky, M. I., & Bajorin, D. F. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt015 · Cited by 91 · see citing works
Self-citationLoeffler, C. M. L., Bruechle, N. O., Jung, M., Seillier, L., Rose, M., Laleh, N. G., Knuechel, R., Brinker, T. J., Trautwein, C., Gaisa, N. T., et al. (2021) · European Urology Focus · doi:10.1016/j.euf.2021.04.007 · Cited by 87 · see citing works
H&E-stained Whole Slide Image Deep Learning Predicts SPOP Mutation State in Prostate CancerPreprint
Schaumberg, A. J., Rubin, M. A., & Fuchs, T. J. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/064279 · Cited by 82 · see citing works
Fibroblast growth factor receptor-3 in urothelial tumorigenesis
Iyer, G., & Milowsky, M. I. (2012) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2011.12.001 · Cited by 72 · see citing works
Self-citationWarrick, J. I., Knowles, M. A., Allory, Y., van der Kwast, T., Grignon, D. J., Kristiansen, G., Egevad, L., Hartmann, A., & Liang Cheng, C. (2020) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001453 · Cited by 57 · see citing works
Genomic Characterization of Upper-Tract Urothelial Carcinoma in Patients With Lynch Syndrome
Donahue, T. F., Bagrodia, A., Audenet, F., Donoghue, M. T. A., Cha, E. K., Sfakianos, J. P., Sperling, D., Al‐Ahmadie, H. A., Clendenning, M., Rosty, C., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00143 · Cited by 55 · see citing works
Self-citationLoss of Rassf1a Synergizes with Deregulated Runx2 Signaling in Tumorigenesis
van der Weyden, L., Papaspyropoulos, A., Poulogiannis, G., Rust, A. G., Rashid, M., Adams, D. J., Arends, M. J., & O’Neill, E. E. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3343 · Cited by 52 · see citing works
Yan, R., Shen, Y., Zhang, X., Xu, P., Wang, J., Li, J., Ren, F., Ye, D., & Zhou, S. K. (2023) · Medical Image Analysis · doi:10.1016/j.media.2023.102824 · Cited by 49 · see citing works
Emerging Critical Role of Molecular Testing in Diagnostic Genitourinary Pathology
Netto, G. J., & Liang Cheng, C. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2011-0471-ra · Cited by 49 · see citing works
Liu, X., Zhang, W., Geng, D., He, J., Zhao, Y., & Li, Y. (2014) · Genetics and Molecular Research · doi:10.4238/2014.february.20.12 · Cited by 44 · see citing works
In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models
Guffanti, F., Chilà, R., Bello, E., Zucchetti, M., Zangarini, M., Ceriani, L., Ferrari, M., Lupi, M., Jacquet-Bescond, A., Burbridge, M. F., et al. (2016) · Neoplasia · doi:10.1016/j.neo.2016.11.008 · Cited by 40 · see citing works
Sung, J., Sun, J., Jeong, B. C., Seo, S. I., Jeon, S. S., Lee, H. M., Choi, H. Y., Kang, S. Y., Choi, Y., & Kwon, G. Y. (2013) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2013.07.015 · Cited by 39 · see citing works
Liu, Z., Xu, X., Li, X., Liu, S., Simoneau, A. R., He, F., Wu, X., & Zi, X. (2013) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0219 · Cited by 39 · see citing works
Kriegsmann, M., Arens, N., Endris, V., Weichert, W., & Kriegsmann, J. (2015) · Diagnostic Pathology · doi:10.1186/s13000-015-0364-3 · Cited by 37 · see citing works
Targeting Signaling Transduction Pathways in Bladder Cancer
Abbosh, P. H., McConkey, D. J., & Plimack, E. R. (2015) · Current Oncology Reports · doi:10.1007/s11912-015-0477-6 · Cited by 37 · see citing works
Al‐Obaidy, K. I., & Liang Cheng, C. (2021) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2020-207115 · Cited by 36 · see citing works
Grivas, P. D., Melas, M., & Papavassiliou, A. G. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.08.006 · Cited by 32 · see citing works
Steurer, S. A., Singer, J. M., Rink, M., Chun, F. K. ‐., Dahlem, R., Simon, R., Burandt, E., Stahl, P. R., Terracciano, L., Schlomm, T., et al. (2014) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2014.06.007 · Cited by 30 · see citing works
Kollmannsberger, C., Britten, C. D., Olszanski, A. J., Walker, J. A., Zang, W., Willard, M. D., Radtke, D. B., Farrington, D. L., Bell‐McGuinn, K. M., & Patnaik, A. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01146-x · Cited by 30 · see citing works
Fromme, J. E., Schmitz, K., Wachter, A., Grzelinski, M., Zielinski, D., Koppel, C., Conradi, L., Homayounfar, K., Hugo, T., Hugo, S., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25941 · Cited by 29 · see citing works
Parizi, M. K., Margulis, V., Lotan, Y., Mori, K., & Shariat, S. F. (2021) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2021.01.025 · Cited by 29 · see citing works
Ramon, A. J., Parmar, C., Carrasco‐Zevallos, O. M., Csiszer, C., Yip, S. S. F., Raciti, P., Stone, N. L., Triantos, S., Quiroz, M. M., Crowley, P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49153-9 · Cited by 28 · see citing works
Chu, C. E., Chen, Z., Whiting, K. A., Ostrovnaya, I., Lenis, A. T., Clinton, T. N., Rammal, R., Ozcan, G. G., Akbulut, D., Başar, M., et al. (2025) · European Urology · doi:10.1016/j.eururo.2025.04.008 · Cited by 28 · see citing works
Self-citationWilliamson, S. R., Wang, M., Montironi, R., Eble, J. N., Antonio Lopez-beltran, B., Zhang, S., Fan, R., Wang, L., Osunkoya, A. O., Koch, M. O., et al. (2014) · Modern Pathology · doi:10.1038/modpathol.2014.48 · Cited by 28 · see citing works
Emerging Bladder Cancer Biomarkers and Targets of Therapy
Netto, G. J., & Tafe, L. J. (2015) · Urologic Clinics of North America · doi:10.1016/j.ucl.2015.08.006 · Cited by 26 · see citing works
Du, X., Lin, B. C., Wang, Q.-R., Li, H., Ingalla, E., Tien, J., Rooney, I. A., Ashkenazi, A., Penuel, E. M., & Qing, J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3336 · Cited by 26 · see citing works
Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples
Kurobe, M., Kojima, T., Nishimura, K., Kandori, S., Kawahara, T., Yoshino, T., Ueno, S., Iizumi, Y., Mitsuzuka, K., Arai, Y., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165109 · Cited by 26 · see citing works
Clinical Applications of Recent Molecular Advances in Urologic Malignancies
Netto, G. J. (2013) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3182863f80 · Cited by 25 · see citing works
Molecular genetics and genomics progress in urothelial bladder cancer
Netto, G. J. (2013) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2013.11.005 · Cited by 22 · see citing works
Condyloma Acuminatum of Urinary Bladder
Samarska, I. V., & Epstein, J. I. (2019) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001339 · Cited by 22 · see citing works
Hodgson, A., van Rhijn, B. W. G., Kim, S. S., Ding, C., Saleeb, R., Vesprini, D., Liu, S. K., Yousef, G. M., van der Kwast, T., Xu, B., et al. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.153186 · Cited by 21 · see citing works
Weickhardt, A. J., Lau, D. K., Hodgson‐Garms, M., Lavis, A., Jenkins, L. J., Vukelic, N., Ioannidis, P., Luk, I. Y., & Mariadason, J. M. (2022) · BMC Cancer · doi:10.1186/s12885-022-09478-4 · Cited by 20 · see citing works
New Treatments for Bladder Cancer: When Will We Make Progress?
Nadal, R., & Joaquim Bellmunt, B. (2014) · Current Treatment Options in Oncology · doi:10.1007/s11864-013-0271-3 · Cited by 20 · see citing works
Sethakorn, N., & O’Donnell, P. H. (2016) · British Journal of Urology · doi:10.1111/bju.13552 · Cited by 19 · see citing works
Udager, A. M., Alva, A. S., & Mehra, R. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000017 · Cited by 19 · see citing works
Targeted therapies in the treatment of urothelial cancers
Aragon‐Ching, J. B., & Trump, D. L. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.03.011 · Cited by 14 · see citing works
Liu, Z., Song, L., Xie, J., Simoneau, A. R., Uchio, E., & Zi, X. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030496 · Cited by 14 · see citing works
Cytotoxic and DNA‐targeted therapy in urothelial cancer: Have we squeezed the lemon enough?
Balar, A. V., & Milowsky, M. I. (2014) · Cancer · doi:10.1002/cncr.28754 · Cited by 13 · see citing works
Self-citationSchnitzler, T., Ortiz‐Brüchle, N., Schneider, U., Lurje, I., Guricová, K., Büchner, A., Schulz, G. B., Heidenreich, A., Gaisa, N. T., Knüchel, R., et al. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00524-6 · Cited by 12 · see citing works
Precursors of urinary bladder cancer: molecular alterations and biomarkers
Taylor, A. S., Acosta, A. M., Al‐Ahmadie, H. A., & Mehra, R. (2022) · Human Pathology · doi:10.1016/j.humpath.2022.06.006 · Cited by 12 · see citing works
Self-citationPerioperative Therapy for Muscle Invasive Bladder Cancer
Leow, J. J. J., Fay, A. P., Mullane, S. A., & Joaquim Bellmunt, B. (2015) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.11.002 · Cited by 12 · see citing works
Organoid models in bladder cancer: From bench to bedside?
Zhao, H., Ho, V. W. S., Liu, K., Chen, X., Wu, H., Chiu, P. K., Chan, L.-Y., Yuen, S. K. K., Leung, D. K.-W., Liu, A. Q., et al. (2025) · Bladder Cancer · doi:10.1177/23523735251330404 · Cited by 8 · see citing works
Zarei, P., & Ghasemi, F. (2024) · Advanced Biomedical Research · doi:10.4103/abr.abr_170_23 · Cited by 8 · see citing works
Characterization of a KLK2-FGFR2 fusion gene in two cases of metastatic prostate cancer
Krook, M. A., Barker, H. D., Chen, H., Reeser, J. W., Wing, M. R., Patacsil, D., Smith, A. M., Dao, T., Bonneville, R., Samorodnitsky, E., et al. (2019) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-019-0145-2 · Cited by 7 · see citing works
Shi, W., Guan, J., Long, Y.-P., Song, Q., Xiong, Q., Qin, B.-Y., Ma, Z., Hu, Y., & Yang, B. Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.915662 · Cited by 6 · see citing works
Molecular Pathology of Bladder Cancer
Netto, G. J. (2012) · Surgical pathology clinics · doi:10.1016/j.path.2012.08.003 · Cited by 5 · see citing works
Molecular Signatures in Urologic Tumors
Larkin, S., & Kyprianou, N. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140918421 · Cited by 5 · see citing works
We are all individuals… bioinformatics in the personalized medicine era
Neste, L. V., & Criekinge, W. V. (2014) · Cellular Oncology · doi:10.1007/s13402-014-0195-3 · Cited by 5 · see citing works
Liu, H., He, W., Wang, B., Xu, K., Han, J., Zheng, J., Ren, J. T., Shao, L., Bo, S., Lü, S., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4571-7 · Cited by 5 · see citing works
Sex bias in FGFR3 somatic mutations in bladder cancer
Meng, X., & Wang, Q.-L. (2024) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000054 · Cited by 3 · see citing works
Clinical Significance of FGFR1 Gene Amplification In Lung Cancer Patients
Schmitz, K., & Schildhaus, H. (2014) · Lung Cancer Management · doi:10.2217/lmt.14.24 · Cited by 3 · see citing works
Novel agents in invasive urothelial cancer.
Balar, A. V., & Milowsky, M. I. (2012) · PubMed · Cited by 3 · see citing works
Self-citationOsterman, C. K., & Milowsky, M. I. (2020) · Cancer · doi:10.1002/cncr.32804 · Cited by 2 · see citing works
Self-citationPathology of Genitourinary Malignancies: Implications for Clinical Management
Wood, L. S., & Zhou, M. (2012) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2012.05.003 · Cited by 1 · see citing works
New Molecular Markers with Diagnostic and Prognostic Values in Bladder Cancer
Al‐Ahmadie, H. A., & Iyer, G. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2044-0_18 · Cited by 1 · see citing works
Self-citationKim, D. S., Choi, Y., Ireland, J. S., Foreman, O., Tam, R. N. W., Patel, R., Schleifman, E., Motlhabi, M., French, D. M., Wong, C. V., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165856 · Cited by 1 · see citing works
FGFR3, a marker suggestive of favorable prognosis in urothelial carcinoma
Khalifa, S. E., Khairy, R. A., & Mostafa, R. R. (2017) · Comparative Clinical Pathology · doi:10.1007/s00580-017-2510-7 · Cited by 1 · see citing works
Gamallat, Y., Afsharpad, M., Hallani, S. E., Maher, C. A., Alimohamed, N. S., Hyndman, E., & Bismar, T. A. (2023) · Cancers · doi:10.3390/cancers15123167 · Cited by 1 · see citing works
Fibroblast growth factor receptor 3 gene expression in Egyptian acute leukemia patients
Eldahshan, D. H., Omar, M. S., Genena, A. M., & Zawam, H. M. (2013) · Comparative Clinical Pathology · doi:10.1007/s00580-013-1778-5
Genetic and Epigenetic Alterations in Urothelial Carcinoma
Al‐Ahmadie, H. A., & Iyer, G. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2044-0_20
Self-citationThe urinary bladder, urachal remnants, urethra, renal pelves, and ureters
Foster, C. S., & Netto, G. J. (2015) · Cambridge University Press eBooks · doi:10.1017/9781139137201.034
Molekulares Tumorboard – Urothelkarzinom
Hupe, M. C., Gakis, G., & Seiler, R. (2019) · Der Urologe · doi:10.1007/s00120-019-0967-5
(2012) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0b013e3283573126
Niglio, S. A., & Galsky, M. D. (2021) · Springer eBooks · doi:10.1007/978-3-030-70646-3_26
Molekulares Tumorboard – Urothelkarzinom
Gakis, G. (2022) · Springer Reference Medizin · doi:10.1007/978-3-642-41168-7_251-1
Molekulares Tumorboard – Urothelkarzinom
Gakis, G. (2023) · Springer Reference Medizin · doi:10.1007/978-3-662-63400-4_251
Genomic profiling of urological malignancies using tissue-based next generation sequencing
Alruwaii, Z. I., Ozcan, G. G., Hassan, O., Liang Cheng, C., & Al‐Obaidy, K. I. (2025) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2025.04.011
Integrated histopathologic modeling of detailed tumor subtypes and actionable biomarkersPreprint
Boehm, K. M., Darmofal, M., Pasha, A., Aukerman, A. T., Lim, R. S., Seffar, E., Pollard, T., Rekhtman, N., Chang, J. C., Kohli, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.14.670351 · Cited by 1 · see citing works
Self-citationWeickhardt, A. J., Lau, D. K., Hodgson‐Garms, M., Lavis, A., Jenkins, L. J., Vukelic, N., Ioannidis, P., Luk, I. Y., & Mariadason, J. M. (2022) · Figshare · doi:10.6084/m9.figshare.19695821
Martelli, F. M., Fanelli, G. N., Stefanizzi, L., Vicentini, C., Marcolini, L., Marletta, S., Giacometti, C., Bertoloni, R., Bertoldi, N., Salvagno, G. L., et al. (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156642
Çağlayan, D., Göktaş, E., Somuncu, M. N., Kılınç, F., Koçak, M. Z., Hendem, E., Yıldız, O., Gürbüz, A. F., Canlar, H., Uğraklı, M., et al. (2026) · Medicina · doi:10.3390/medicina62102026
Molecular Testing in Urothelial Tumors
Gabril, M. Y., & Yousef, G. M. (2014) · Springer eBooks · doi:10.1007/978-1-4899-8050-2_18
- Authors
- Al‐Ahmadie, H. A., Iyer, G., Janakiraman, M., Lin, O., Heguy, A., Tickoo, S. K., Fine, S. W., Gopalan, A., Chen, Y., Balar, A., Riches, J., Bochner, B., Dalbagni, G., Bajorin, D. F., Reuter, V. E., Milowsky, M. I., & Solit, D. B.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Solit, David B.
- ORCID
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 2011-05-05
- Volume
- 224
- Issue
- 2
- Pages
- 270-279
- ISSN
- 0022-3417 (ISSN-L)
- 1096-9896
- PMC
- PMC3235805
- OpenAlex
- W1982643760
- Cited by
- 88
- References
- 40
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 4 · 2023: 3 · 2022: 6 · 2021: 5 · 2020: 4 · 2019: 5 · 2018: 4 · 2017: 2 · 2016: 5 · 2015: 11 · 2014: 13 · 2013: 10 · 2012: 9
- FWCI
- 10.49
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Pathology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- American Association for Cancer Research-Henry Shepard Bladder Cancer Research Fund
- Topics
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- FGFR3 mutation, high-grade urothelial carcinoma, somatic mutations, histological subtypes, targeted therapy, lymph node metastasis, tumor heterogeneity
- MeSH terms
- Aged, Aged, 80 and over, Urinary Bladder Neoplasms, Female, Humans, Lymphatic Metastasis, Male, Middle Aged, Mutation, Neoplasm Invasiveness, Neoplasm Proteins, Prognosis, Retrospective Studies, Survival Analysis, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Receptor, Fibroblast Growth Factor, Type 3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
